HRP20191725T1 - Orvepitant za liječenje kroničnog kašlja - Google Patents
Orvepitant za liječenje kroničnog kašlja Download PDFInfo
- Publication number
- HRP20191725T1 HRP20191725T1 HRP20191725TT HRP20191725T HRP20191725T1 HR P20191725 T1 HRP20191725 T1 HR P20191725T1 HR P20191725T T HRP20191725T T HR P20191725TT HR P20191725 T HRP20191725 T HR P20191725T HR P20191725 T1 HRP20191725 T1 HR P20191725T1
- Authority
- HR
- Croatia
- Prior art keywords
- orvepitant
- pharmaceutically acceptable
- use according
- acceptable salt
- phenyl
- Prior art date
Links
- 206010011224 Cough Diseases 0.000 title claims 16
- XWNBGDJPEXZSQM-VZOBGQTKSA-N (2r,4s)-4-[(8as)-6-oxo-1,3,4,7,8,8a-hexahydropyrrolo[1,2-a]pyrazin-2-yl]-n-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-n-methylpiperidine-1-carboxamide Chemical compound C1([C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)N2C[C@H]3N(C(CC3)=O)CC2)=CC=C(F)C=C1C XWNBGDJPEXZSQM-VZOBGQTKSA-N 0.000 title claims 15
- 229950006784 orvepitant Drugs 0.000 title claims 15
- 208000013116 chronic cough Diseases 0.000 title claims 13
- 150000003839 salts Chemical class 0.000 claims 17
- IPACOHTZCSBGBV-WUXDIRCFSA-N (2r,4s)-4-[(8as)-6-oxo-1,3,4,7,8,8a-hexahydropyrrolo[1,2-a]pyrazin-2-yl]-n-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-n-methylpiperidine-1-carboxamide;(z)-but-2-enedioic acid Chemical group OC(=O)\C=C/C(O)=O.C1([C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)N2C[C@H]3N(C(CC3)=O)CC2)=CC=C(F)C=C1C IPACOHTZCSBGBV-WUXDIRCFSA-N 0.000 claims 8
- -1 [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-( (8aS)-6-oxo-hexahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidine-1-carboxylic acid Chemical compound 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 3
- HLWURFKMDLAKOD-UHFFFAOYSA-N 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide Chemical compound C1=C(S(N)(=O)=O)C(OC)=CC(C(C)C)=C1OC1=CN=C(N)N=C1N HLWURFKMDLAKOD-UHFFFAOYSA-N 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 2
- 102100040460 P2X purinoceptor 3 Human genes 0.000 claims 2
- 101710189970 P2X purinoceptor 3 Proteins 0.000 claims 2
- 206010070488 Upper-airway cough syndrome Diseases 0.000 claims 2
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 claims 2
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 239000000111 purinergic antagonist Substances 0.000 claims 2
- 229940121374 purinergic receptor antagonist Drugs 0.000 claims 2
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 claims 1
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010065563 Eosinophilic bronchitis Diseases 0.000 claims 1
- 206010024119 Left ventricular failure Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000037581 Persistent Infection Diseases 0.000 claims 1
- 208000006193 Pulmonary infarction Diseases 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical group CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 1
- 208000007474 aortic aneurysm Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 229960001361 ipratropium bromide Drugs 0.000 claims 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical group O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 239000003149 muscarinic antagonist Substances 0.000 claims 1
- 208000025426 neoplasm of thorax Diseases 0.000 claims 1
- 208000000689 peptic esophagitis Diseases 0.000 claims 1
- 230000007575 pulmonary infarction Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 229960002052 salbutamol Drugs 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 201000003957 thoracic cancer Diseases 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (21)
1. [1-(R)-(3,5-bis-trifluorometil-fenil)-etil]-metilamid 2-(R)-(4-Fluoro-2-metil-fenil)-4-(S)-((8aS)-6-okso-heksahidro-pirolo[1,2-a]-pirazin-2-il)-piperidin-1-karboksilne kiseline (orvepitant) ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju kroničnog kašlja.
2. Orvepitant ili njegova farmaceutski prihvatljiva sol, za uporabu u skladu s patentnim zahtjevom 1, naznačen time što je kronični kašalj kronični refraktorni kašalj.
3. Orvepitant ili njegova farmaceutski prihvatljiva sol, za uporabu u skladu s patentnim zahtjevom 1 ili 2, pri čemu je kronični kašalj posljedica ili je povezan sa sarkoidozom, emfizemom ili idiopatskom plućnom fibrozom (IPF).
4. Orvepitant ili njegova farmaceutski prihvatljiva sol, za uporabu u skladu s patentnim zahtjevom 1 ili 2, pri čemu je kronični kašalj posljedica ili je povezan s astmom, kroničnim bronhitisom, kroničnim postnazalnim curenjem, eozinofilnim bronhitisom ili kroničnom opstruktivnom bolešću pluća (COPD).
5. Orvepitant ili njegova farmaceutski prihvatljiva sol, za uporabu u skladu s patentnim zahtjevom 1 ili 2, pri čemu je kronični kašalj posljedica ili je povezan s kroničnim infekcijama kao što su bronhiektazija, tuberkuloza ili cistična fibroza.
6. Orvepitant ili njegova farmaceutski prihvatljiva sol, za uporabu u skladu s patentnim zahtjevom 1 ili 2, pri čemu je kronični kašalj posljedica ili je povezan s tumorima pluća kao što su bronhogeni karcinom, karcinom alveolarnih stanica, benigni tumori dišnih puteva ili tumori sredoprsja.
7. Orvepitant ili njegova farmaceutski prihvatljiva sol, za uporabu u skladu s patentnim zahtjevom 1 ili 2, pri čemu je kronični kašalj posljedica ili je povezan s kardiovaskularnom bolešću kao što su zatajenje lijeve klijetke, infarkt pluća ili aneurizma aorte.
8. Orvepitant ili njegova farmaceutski prihvatljiva sol, za uporabu u skladu s patentnim zahtjevom 1 ili 2, pri čemu je kronični kašalj posljedica ili je povezan s refluksnim ezofagitisom, rekurentnom aspiracijom, endobronhijalnim šavovima, sindromom postnazalnog curenja ili rinosinusitisom.
9. Orvepitant ili njegova farmaceutski prihvatljiva sol, za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 8, pri čemu je farmaceutski prihvatljiva sol orvepitanta maleat.
10. Orvepitant maleat za uporabu u skladu s patentnim zahtjevom 9, pri čemu je orvepitant maleat orvepitant maleat oblika 1.
11. [1-(R)-(3,5-bis-trifluorometil-fenil)-etil]-metilamid 2-(R)-(4-Fluoro-2-metil-fenil)-4-(S)-((8aS)-6-okso-heksahidro-pirolo[1,2-a]-pirazin-2-il)-piperidin-1-karboksilne kiseline (orvepitant) ili njegova farmaceutski prihvatljiva sol u kombinaciji s jednim ili više terapeutskih tvari, odabranih od antagonista P2X3 purinergičkog receptora, antagonista muskarinskog receptora ili agonista beta-2 adrenoceptora; za uporabu u liječenju kroničnog kašlja.
12. Kombinacija za uporabu u skladu s patentnim zahtjevom 11, pri čemu je kronični kašalj kronični refraktorni kašalj.
13. Kombinacija za uporabu u skladu sa patentnim zahtjevom 11 ili 12, pri čemu su antagonisti P2X3 purinergičkog receptora 5-(2,4-diamino-pirimidin-5-iloksi)-4-izopropil-2-metoksi-benzensulfonamid (AF-219) ili AF-130.
14. Kombinacija za uporabu u skladu s patentnim zahtjevom 11 ili 12, pri čemu je agonist beta-2 adrenoceptora salbutamol.
15. Kombinacija za uporabu u skladu s patentnim zahtjevom 11 ili 12, pri čemu je antagonist muskarinskog receptora ipratropij bromid.
16. Kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 11-15, pri čemu je farmaceutski prihvatljiva sol orvepitanta maleat.
17. Kombinacija za uporabu u skladu s patentnim zahtjevom 16, pri čemu je orvepitant maleat bezvodni kristalni oblik 1.
18. Farmaceutski pripravak koji sadrži [1-(R)-(3,5-bis-trifluorometil-fenil)-etil]-metilamid 2-(R)-(4-Fluoro-2-metil-fenil)-4-(S)-((8aS)-6-okso-heksahidro-pirolo[1,2-a]-pirazin-2-il)-piperidin-1-karboksilne kiseline (orvepitant) ili njegovu farmaceutski prihvatljivu sol i jedan ili više farmaceutski prihvatljivih nosača ili ekscipijenata za uporabu u liječenju kroničnog kašlja.
19. Farmaceutski pripravak koji sadrži [1-(R)-(3,5-bis-trifluorometil-fenil)-etil]-metilamid 2-(R)-(4-Fluoro-2-metil-fenil)-4-(S)-((8aS)-6-okso-heksahidro-pirolo[1,2-a]-pirazin-2-il)-piperidin-1-karboksilne kiseline (orvepitant) ili farmaceutski prihvatljivu sol i jedan ili više farmaceutski prihvatljivih nosača ili ekscipijenata za uporabu u skladu s patentnim zahtjevom 18, pri čemu je kronični kašalj kronični refraktorni kašalj.
20. Farmaceutski pripravak koji sadrži [1-(R)-(3,5-bis-trifluorometil-fenil)-etil]-metilamid 2-(R)-(4-Fluoro-2-metil-fenil)-4-(S)-((8aS)-6-okso-heksahidro-pirolo[1,2-a]-pirazin-2-il)-piperidin-1-karboksilne kiseline (orvepitant) ili farmaceutski prihvatljivu sol i jedan ili više farmaceutski prihvatljivih nosača ili ekscipijenata za uporabu u skladu s patentnim zahtjevom 18 ili 19, pri čemu je farmaceutski prihvatljiva sol orvepitanta maleat.
21. Farmaceutski pripravak koji sadrži [1-(R)-(3,5-bis-trifluorometil-fenil)-etil]-metilamid 2-(R)-(4-Fluoro-2-metil-fenil)-4-(S)-((8aS)-6-okso-heksahidro-pirolo[1,2-a]-pirazin-2-il)-piperidin-1-karboksilne kiseline (orvepitant) ili farmaceutski prihvatljivu sol i jedan ili više farmaceutski prihvatljivih nosača ili ekscipijenata za uporabu u skladu s patentnim zahtjevom 20, pri čemu je orvepitant maleat bezvodni kristalni oblik 1.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276237P | 2016-01-08 | 2016-01-08 | |
| US201662408921P | 2016-10-17 | 2016-10-17 | |
| PCT/EP2016/082698 WO2017118584A1 (en) | 2016-01-08 | 2016-12-27 | Orvepitant for the treatment of chronic cough |
| EP16819325.8A EP3377064B1 (en) | 2016-01-08 | 2016-12-27 | Orvepitant for the treatment of chronic cough |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191725T1 true HRP20191725T1 (hr) | 2019-12-27 |
Family
ID=57629591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191725TT HRP20191725T1 (hr) | 2016-01-08 | 2019-09-24 | Orvepitant za liječenje kroničnog kašlja |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9750739B2 (hr) |
| EP (1) | EP3377064B1 (hr) |
| JP (1) | JP6621534B2 (hr) |
| KR (1) | KR102136017B1 (hr) |
| CN (2) | CN108430475B (hr) |
| AU (1) | AU2016384267B2 (hr) |
| BR (1) | BR112018013903B1 (hr) |
| CA (1) | CA3009283C (hr) |
| CY (1) | CY1122170T1 (hr) |
| DK (1) | DK3377064T3 (hr) |
| ES (1) | ES2738678T3 (hr) |
| HR (1) | HRP20191725T1 (hr) |
| HU (1) | HUE045764T2 (hr) |
| LT (1) | LT3377064T (hr) |
| MX (1) | MX371178B (hr) |
| PL (1) | PL3377064T3 (hr) |
| PT (1) | PT3377064T (hr) |
| RS (1) | RS59313B1 (hr) |
| RU (1) | RU2746601C2 (hr) |
| SI (1) | SI3377064T1 (hr) |
| WO (1) | WO2017118584A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180235931A1 (en) * | 2017-01-17 | 2018-08-23 | Menlo Therapeutics Inc. | Use of neurokinin-1 antagonists as antitussives |
| SG11202100580UA (en) * | 2018-07-23 | 2021-02-25 | Trevi Therapeutics Inc | Treatment of chronic cough, breathlessness and dyspnea |
| CN112823795B (zh) * | 2019-11-20 | 2023-04-14 | 天津医科大学总医院 | 一种特发性肺纤维化药物组合及其应用 |
| IL296635A (en) * | 2020-04-03 | 2022-11-01 | Nerre Therapeutics Ltd | An nk-1 receptor antagonist for the treatment of a disease selected from sepsis, septic shock, acute respiratory distress syndrome (ARDS), or multiple organ dysfunction syndrome (MODS) |
| CA3177477A1 (en) | 2020-06-02 | 2021-12-09 | Nerre Therapeutics Limited | Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs |
| CN114732818B (zh) * | 2022-04-29 | 2023-02-10 | 首都医科大学附属北京胸科医院 | 一种抗特发性肺纤维化药物尼达尼布在结核病治疗中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ321575A (en) * | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
| GB0203020D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| GB0806652D0 (en) * | 2008-04-11 | 2008-05-14 | Glaxo Group Ltd | Anhydrous crystal form of orvepitant maleate |
| US9603849B2 (en) * | 2012-10-11 | 2017-03-28 | Nerre Therapeutics Limited | Uses of orvepitant |
-
2016
- 2016-12-27 SI SI201630402T patent/SI3377064T1/sl unknown
- 2016-12-27 HU HUE16819325A patent/HUE045764T2/hu unknown
- 2016-12-27 LT LTEP16819325.8T patent/LT3377064T/lt unknown
- 2016-12-27 KR KR1020187022777A patent/KR102136017B1/ko active IP Right Grant
- 2016-12-27 CA CA3009283A patent/CA3009283C/en active Active
- 2016-12-27 BR BR112018013903-3A patent/BR112018013903B1/pt active IP Right Grant
- 2016-12-27 DK DK16819325.8T patent/DK3377064T3/da active
- 2016-12-27 RU RU2018122121A patent/RU2746601C2/ru active
- 2016-12-27 CN CN201680078401.6A patent/CN108430475B/zh active Active
- 2016-12-27 MX MX2018008439A patent/MX371178B/es active IP Right Grant
- 2016-12-27 EP EP16819325.8A patent/EP3377064B1/en active Active
- 2016-12-27 JP JP2018532045A patent/JP6621534B2/ja active Active
- 2016-12-27 AU AU2016384267A patent/AU2016384267B2/en active Active
- 2016-12-27 US US15/390,770 patent/US9750739B2/en active Active
- 2016-12-27 RS RSP20191236 patent/RS59313B1/sr unknown
- 2016-12-27 ES ES16819325T patent/ES2738678T3/es active Active
- 2016-12-27 WO PCT/EP2016/082698 patent/WO2017118584A1/en active Application Filing
- 2016-12-27 CN CN202110372520.5A patent/CN113274392A/zh active Pending
- 2016-12-27 PL PL16819325T patent/PL3377064T3/pl unknown
- 2016-12-27 PT PT16819325T patent/PT3377064T/pt unknown
-
2017
- 2017-08-01 US US15/665,640 patent/US20170326140A1/en not_active Abandoned
-
2019
- 2019-09-03 CY CY20191100924T patent/CY1122170T1/el unknown
- 2019-09-24 HR HRP20191725TT patent/HRP20191725T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019501162A (ja) | 2019-01-17 |
| CN113274392A (zh) | 2021-08-20 |
| ES2738678T3 (es) | 2020-01-24 |
| KR20180100651A (ko) | 2018-09-11 |
| BR112018013903A2 (pt) | 2018-12-18 |
| CA3009283C (en) | 2023-10-03 |
| CY1122170T1 (el) | 2020-11-25 |
| US9750739B2 (en) | 2017-09-05 |
| BR112018013903B1 (pt) | 2023-11-07 |
| CN108430475B (zh) | 2021-03-16 |
| US20170196860A1 (en) | 2017-07-13 |
| RS59313B1 (sr) | 2019-10-31 |
| WO2017118584A1 (en) | 2017-07-13 |
| HUE045764T2 (hu) | 2020-01-28 |
| CA3009283A1 (en) | 2017-07-13 |
| SI3377064T1 (sl) | 2019-11-29 |
| LT3377064T (lt) | 2019-09-10 |
| RU2018122121A (ru) | 2020-02-11 |
| JP6621534B2 (ja) | 2019-12-18 |
| MX371178B (es) | 2020-01-21 |
| KR102136017B1 (ko) | 2020-07-20 |
| AU2016384267B2 (en) | 2022-02-03 |
| DK3377064T3 (da) | 2019-09-23 |
| PT3377064T (pt) | 2019-07-23 |
| EP3377064B1 (en) | 2019-06-26 |
| EP3377064A1 (en) | 2018-09-26 |
| MX2018008439A (es) | 2018-08-14 |
| PL3377064T3 (pl) | 2020-02-28 |
| US20170326140A1 (en) | 2017-11-16 |
| AU2016384267A1 (en) | 2018-07-05 |
| RU2018122121A3 (hr) | 2020-06-26 |
| RU2746601C2 (ru) | 2021-04-16 |
| CN108430475A (zh) | 2018-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191725T1 (hr) | Orvepitant za liječenje kroničnog kašlja | |
| HRP20170624T1 (hr) | Derivat piridina i pirazina za liječenje kronične opstrukcijske plućne bolesti | |
| JP2017504611A5 (hr) | ||
| SA519402319B1 (ar) | Rho- مشتقات أميد التيروسين كمثبطات لإنزيم الكيناز | |
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| MX2019005526A (es) | Derivados biciclicos de dihidropirimidina-carboxamida como inhibidores de rho-cinasa. | |
| HRP20170873T1 (hr) | Monociklički derivat piridina | |
| JP2017528507A5 (hr) | ||
| PE20080944A1 (es) | Derivados de pirimidina como inhibidores del receptor de cinasa activina(alk-5) | |
| SI3009428T1 (en) | DIAMINO HETEROCYCLIC CARBOSAMIDE COMPOUNDS | |
| JP2018090566A5 (hr) | ||
| TW200714586A (en) | Crystalline forms of a biphenyl compound | |
| JP2009533427A5 (hr) | ||
| MX2016014756A (es) | Nuevo tratamiento. | |
| WO2008054748A3 (en) | Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto | |
| MX2010003923A (es) | Formulacion farmaceutica de valsartan. | |
| HRP20200662T1 (hr) | Ljekoviti pripravak koji sadrži spoj diamino heterocikličkog karboksamida kao aktivni sastojak | |
| JP2019505594A5 (hr) | ||
| HRP20180602T1 (hr) | Farmaceutska kombinacija | |
| JP2012519182A5 (hr) | ||
| JP2015526455A5 (hr) | ||
| WO2012113850A3 (en) | (PYRIDIN-4-YL)BENZYLAMIDES AS ALLOSTERIC MODULATORS OF ALPHA 7 nAChR | |
| BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| MX2021000270A (es) | Derivados de la tirosina amida como inhibidores de la rho- cinasa. | |
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением |